Ertapenem - a potent treatment for clinical and quality of life improvement in patients with hidradenitis suppurativa

Document Type

Article

Publication Date

9-1-2018

Publication Title

International journal of dermatology

Abstract

BACKGROUND: A paucity of knowledge exists regarding the use of ertapenem in hidradenitis suppurativa. Our retrospective chart review and telephone interview aims to investigate the utility of intravenous ertapenem in severe, refractory hidradenitis suppurativa.

METHODS: This retrospective chart review and telephone interview included patients with severe, refractory hidradenitis suppurativa treated with intravenous ertapenem between March 2013 and December 2016. Data were obtained from medical charts. During the telephone interview, patients were asked questions relating to satisfaction, quality of life changes, and disease state changes with ertapenem therapy.

RESULTS: A total of 36 patients including 22 females and 14 males with Hurley stage II or III hidradenitis suppurativa were included. Thirty-five patients (97.2%), demonstrated improvements in hidradenitis suppurativa with ertapenem treatment. In total, 28 patients participated in our telephone interview. Twenty patients (71.4%) were very satisfied (n = 12) or satisfied (n = 8). Quality of life improved in 85.7% of patients (n = 24).

CONCLUSION: Following ertapenem therapy, patients reported improvements in quality of life. This treatment appears promising as an adjunct to biologics or as a bridge to surgery in the treatment of severe, refractory hidradenitis suppurativa.

Medical Subject Headings

Administration, Intravenous; Adult; Anti-Bacterial Agents; Drug Therapy, Combination; Ertapenem; Female; Hidradenitis Suppurativa; Humans; Male; Patient Satisfaction; Quality of Life; Recurrence; Retreatment; Retrospective Studies; Severity of Illness Index

PubMed ID

29774531

Volume

57

Issue

9

First Page

1088

Last Page

1093

Find It @ Sladen

Share

COinS